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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract Atherosclerosis occurs as a result of the oxidation of low-density lipoprotein (LDL)
deposits, which later form plaques. Hyperglycemia, which occurs in patients with type 2 dia-
betes mellitus, is a risk factor for this kind of vascular damage. Oxidative stress from hydrogen
peroxide (H2O2) is increased in patients with hyperglycemia and therefore an antioxidant agent
is required to prevent the destruction of the walls of blood vessels. This study aimed to show
that Ganoderma lucidum polysaccharide peptide (PsP) can decrease the formation of H2O2.
The study was an experimental in vivo post-test with control group design. Thirty-five Wistar
rats (Rattus norwegicus) were divided into five groups (a normal diet group, a hypercholesterol
diet group, and hypercholesterol groups that received doses of 50 mg/kg, 150 mg/kg, and
300 mg/kg body weight PsP). The parameters determined in this study were the level of
H2O2, the lipid profile, insulin resistance, and the amounts of perivascular adipocyte tissue
(PVAT), foam cells, and plaques. Each treatment group showed significant results for the
administration of PsP using the one-way analysis of variance test (p < 0.050) for the reduction
of H2O2 (pZ 0.003), the lipid profile (cholesterol total and triglyceride; pZ 0.010, pZ 0.001),
insulin resistance (p Z 0.003), the amount of PVAT (p <0.001), and plaques (p <0.001). The
decrease in foam cells was insignificant (pZ 0.149), although an obvious pattern of reduction
as a result of PsP treatment was observed. PsP from G. lucidum is a potent antioxidant and mayin Hospital, Teuku Daoed Beureuh 108, Banda Aceh 23126, Indonesia.
ail.com (T. Heriansyah).
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32 T. Heriansyah et al.prevent the pathophysiology of atherosclerosis in patients with type 2 diabetes mellitus. The
optimum dose in patients with type 2 diabetes mellitus is 300 mg/kg body weight. Further
studies are required to determine the antioxidant effects of G. lucidum PsP and its benefits
in the management of type 2 diabetes mellitus.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Cardiovascular disease is the major cause of death world-
wide. It is estimated that 17.3 million people died from
cardiovascular disease in 2008, representing 30% of global
deaths.1 Approximately 128 million people worldwide have
multiple risk factors that increase the prevalence of car-
diovascular disease. Some of these risk factors include hy-
pertension, both active and passive smoking, obesity,
dyslipidemia, high cholesterol, stress, a lack of consump-
tion of fruit, a lack of physical activity, and metabolic
diseases such as diabetes mellitus.2
Diabetes mellitus is the major risk factor for the devel-
opment of atherosclerosis and its clinical manifestations,
including coronary artery disease, stroke, and peripheral
vascular disease.3 People who have either type 1 or type 2
diabetes mellitus have a two to six times greater risk of
developing atherosclerosis than non-diabetic patients.4
About 18.8 million Americans have been diagnosed with
diabetes mellitus and another 7 million are estimated to
have undetected diabetes.5 Death in people with diabetes
is a result of complications from the disease. One of the
macrovascular complications of diabetes is the process of
atherosclerosis induced by the long-term inflammation of
the walls of the coronary arteries and the peripheral blood
vessels.6
One of the major theories for the formation of athero-
sclerotic plaques is oxidative stress. Oxidative stress occurs
due to a lack of antioxidants inside the human body so that
it is unable to eradicate reactive oxygen species (ROS) such
as hydrogen peroxide (H2O2). An excessive intake of calo-
ries can lead to an increase in the activity of the citric acid
cycle, which produces ROS. Mitochondrial ROS production is
reduced by inhibiting the role of insulin in the absorption of
nutrients, such as pyruvate and fatty acids, in cells. These
mechanisms can cause insulin resistance in tissues.7
Insulin resistance is a condition associated with the
failure of target organs to respond to the activity of the
hormone insulin. Insulin resistance also causes hyper-
insulinemia, which later progresses to glucose intolerance,
atherogenic dyslipidemia, hypertriglyceridemia, and
increased blood pressure.8 Insulin resistance generates
endothelial dysfunction that causes inflammation in the
endothelial wall and therefore atherosclerotic plaques are
easily formed.7
In addition to insulin resistance, hyperglycemia can
affect endothelial functions. Hyperglycemia induces the
overproduction of superoxide by increasing the formation
of nitric oxide. In its turn, nitric oxide, and other free
radicals that can oxidize low-density lipoprotein (LDL) tooxidized LDL (oxLDL) (H2O2), will cause an inflammatory
response that stimulates macrophages to phagocytose
oxLDL to form foam cells. The appearance of foam cells
signifies the beginning of atherosclerotic process in dia-
betes mellitus.7
The management of diabetes mellitus is currently
focused on keeping blood glucose levels within normal
limits. Antioxidant treatment also plays an important part
in improving diabetes.9 Increases in oxidative stress, such
as the presence of H2O2, may accelerate the progression of
diabetic complications through the metabolism of glucose
and free fatty acid overload in patients with diabetes and
insulin resistance.10 A source of antioxidants, such as can
be found in polysaccharide peptides (PsPs), is required to
compensate for the increase in oxidative stress.
PsPs are protein-bound polysaccharide extracts that may
be obtained by extraction from a variety of plants and
fungi, one of which is Ganoderma lucidum.11 Some studies
have suggested that this extract has a therapeutic benefit
in increasing body weight, serum insulin, and high-density
lipoprotein (HDL), as well as decreasing fasting blood
glucose and levels of total cholesterol, LDL, and tri-
glycerides.11 We report here the effects of G. lucidum PsP
on the levels of H2O2, the lipid profile, insulin resistance
values, atherosclerotic plaques, foam cells, and the thick-
ness of perivascular adipocyte tissue (PVAT) in a Wistar rat
model of type 2 diabetes mellitus.
Materials and methods
Ganoderma lucidum polysaccharide peptide
PsP was supplied by Sahabat Lingkungan Hidup Partner
Labs, Surabaya, Indonesia in the form of capsules contain-
ing 250 mg of an extract of G. lucidum. Each gram of PsP
contained 200 mg of b-D-glucan. PsP was administrated to
the animal models daily via oral gavage in the last 4 weeks
of the study. The hypercholesterol diet was obtained from
the Laboratory of Pharmacology, Medical Faculty, Brawi-
jaya University and was given to the rats for 12 weeks.
Animals
Thirty-five Wistar rats (Rattus norwegicus), 8 weeks of age
and weighing 150e200 g, were obtained from CV Gamma
Scientific Biolab (Malang, Indonesia). These rats were
divided into five groups: a normal diet group; a group fed a
hypercholesterol diet and given a streptozotocin (STZ) in-
jection (30 mg/kg body weight; BioWorld Products Inc.,
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jaya University; and three groups fed a hypercholesterol
diet, given an STZ (30 mg/kg body weight) injection, and
administered with three different doses of G. lucidum PsP
(50 mg/kg, 150 mg/kg, and 300 mg/kg body weight). Each
treatment group consisted of seven rats. The hyper-
cholesterol diet was given throughout this study (12 weeks)
and STZ 30 mg/kg body weight was administered once to
induce type 2 diabetes mellitus.Blood glucose measurements
A dose of 30 mg/kg body weight STZ was administered prior
to the first measurement of blood glucose to induce type 2
diabetes mellitus. Type 2 diabetes mellitus was diagnosed
after measurement of the blood glucose level with a Glu-
coDR blood glucose test meter (All Medicus Co. Ltd, Don-
gan-gu, Anyang-si, Korea). Type 2 diabetes mellitus was
diagnosed after obtaining blood glucose levels >200 mg/dL
in the rats.Tissue sampling
Tissues from the rats were observed at the end of this study
after surgically removing aortic tissues and blood samples
via cardiac puncture. The blood samples were preserved in
the Laboratory of Physiology, Brawijaya University, Malang,
Indonesia and the aortic tissues were prepared by a frozen
section technique and hematoxylineeosin staining before
being examined microscopically in the Laboratory of Pa-
thology and Anatomy, Brawijaya University.H2O2 analysis
Levels of H2O2 in rat plasma were measured using a color-
imetric hydrogen peroxide kit (Assay Design, Abcam, Cam-
bridge, MA, USA) and observed at 570 nm using an enzyme-
linked immunoabsorbent assay reader (ELISA Kit,
Boehringer-Mannheim GMBH, Mannheim, Germany).Measurement of lipid profile levels
The lipid profiles were measured in the blood serum of rats
by counting the levels of lipids using a Cobas Mira Analyzer
(PT Roche Indonesia, Jakarta, Indonesia).Measurements of foam cells, plaques, and PVAT
The aortic tissues were prepared by a frozen section
technique and stained with hematoxylineeosin. After
preparation of the aortic tissues, the atherosclerotic
plaques, foam cells, and the thickness of PVAT were
measured using a microscope with a magnification of 400
and dotSlide Olyvia version 2.4 software (Olympus Amer-
ica Inc., Center Valley, PA, USA). Examination and calcu-
lation of the number of foam cells were performed for
each 10 microscope fields after taking images of the aortic
tissues.Measurement of insulin resistance
Plasma insulin levels were measured using the enzyme-
linked immunoabsorbent assay reader kit (Boehringer-
Mannheim) after the blood glucose had been measured
using the GlucoDR blood glucose meter. Normal values of
plasma insulin levels are lower than 2500 pg/mL. The in-
sulin resistance was calculated using the insulin sensitivity
index calculation as follows:
ISI Z Ln (FBG  FINS)1
where ISI Z insulin sensitivity index; FBG Z fasting blood
glucose; and FINS Z fasting plasma insulin. Insulin resis-
tance is confirmed if the value of the insulin sensitivity
index is < 1.
Ethics
We obtained ethical approval for the animal treatment and
experimental processes in this study from the Ethics Com-
mittee for Health Research Number 462/EC/KEPK/08/2013.
Statistical analysis
The one-way analysis of variance (ANOVA) test was used to
determine the effects of PsP on H2O2, the lipid profile, in-
sulin resistance, PVAT, foam cells, and atherosclerotic
plaques in Wistar rats with type 2 diabetes mellitus. This
analysis was continued by the post hoc test using the
Duncan method to detect differences in parameters in each
treatment group. SPSS software version 20 (IBM Corpora-
tion, New York, NY, USA) was used for data analysis.
Results
Table 1 gives the results of the analysis of the studied pa-
rameters using the one-way ANOVA (p < 0.050) and post hoc
Duncan tests. The parameters were measured in all treat-
ment groups to observe the advantages of the administra-
tion of PsP. The significance of the administration of PsP
was determined after the p values taken from the mea-
surements of the parameters were compared with the
standard p value of the ANOVA test.
There were significant results for the effect of the
administration of G. lucidum PsP on the decrease in the
values of some parameters representative of the existence
of vascular injury. G. lucidum PsP is beneficial in lowering
the levels of H2O2, lipid profiles (total cholesterol and tri-
glyceride), insulin resistance, PVAT, and plaques (one-way
ANOVA p < 0.050). For the treatment groups, the highest
values of the parameters were in the hypercholesterol diet
groups and the lowest values were in the normal diet group.
The results of the post hoc Duncan test revealed significant
differences in the levels of these parameters between the
hypercholesterol diet groups, the normal diet group, and
the hypercholesterol groups that received G. lucidum PsP
300 mg/kg body weight.
However, the decrease in foam cells showed a different
insignificant pattern after being analyzed with the one-way
ANOVA test (p < 0.050). The highest amount of foam cells
Table 1 Measurement and analysis of parameters by ANOVA and post hoc Duncan tests.
Parameter Treatment groups p (one-way
ANOVA
p < 0.050)
Hypercholesterol
diet
Normal diet Diabetes
mellitus
þ PsP 50 mg/kg
body weight
Diabetes mellitus
PsP 150 mg/kg
body weight
Diabetes mellitus
PsP 300 mg/kg
body weight
H2O2 (nmol) 178.39  86.86
(80.13e286.90)
14.25  3.30
(9.25e18.00)
120.62  48.77
(60.38e171.63)
120.25  57.91
(31.13e177.60)
165.38  67.53
(82.75e235.75)
0.003*
Lipid profile
Total cholesterol
(mg/dL)
130.65  59.68
(89.00e233.00)
47.20  9.96
(37.00e61.00)
115.75  20.46
(81.00e132.00)
103.05  34.71
(62.00e158.00)
89.50  21.73
(66.00e115.00)
0.010*
Triglycerides
(mg/dL)
661.60  217.13
(358.00e882.00)
76.20  24.68
(42.00e106.00)
537.60  231.18
(204.00e762.00)
347.80  198.67
(141.00e571.00)
274.80  183.63
(78.00e528.00)
0.001*
Insulin resistance 1.18  0.71
(1.60 to 0.11)
1.30  0.55
(0.79e1.89)
0.99  0.91
(1.67 to 0.04)
4.04  0.54
(0.03e0.78)
5.44  0.27
(0.36e0.85)
0.003*
Thickness of
perivascular
adipose tissue
(mm)
179.46  16.50
(159.51e204.42)
88.41  6.68
(78.31e96.77)
128.84  18.85
(110.02e155.25)
111.01  9.51
(99.71e122.06)
103.79  8.94
(87.62e109.02)
<0.001*
Number of foam
cells (cells/10
fields)
(0.00e26.00) 4.500  1.06
(3.00e6.00)
18.00  14.90
(0.00e40.00)
12.00  1.41
(10.00e14.00)
7.75  7.36
(2.00e20.00)
0.149
Plaque (mm2) 626.25  142.41
(450e825)
67.50  25.92
(25e81.25)
600.00  137.85
(412.5e793.75)
411.25  59.67
(0e493.75)
361.25  74.53
(287.5e743.75)
<0.001*
Data are presented as mean standard deviation (range) values. All the values of the parameters have been corrected into International
Standard of Mathematics (decimals).
*p < 0.05 indicates statistically significant difference.
ANOVA Z analysis of variance; PsP Z polysaccharide peptide.
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a G. lucidum PsP dose of 50 mg/kg body weight. The lowest
amount of foam cells was found in the normal diet group.
This disorder results in p values for the foam cells to be
higher than the probability value of p < 0.050 (p Z 0.149)
and cannot be further processed using the post hoc Duncan
test to determine the difference between the treatment
groups. Although the difference is not statistically signifi-
cant, the result shows that G. lucidum PsP can greatly
reduce the amount of foam cells, with the lowest amount
of foam cells in the hypercholesterol group with 300 mg/kg
body weight PsP (note the amount of foam cells between
the treatment groups that received both hypercholesterol
diet and G. lucidum PsP). Other histopathological images of
several parameters (PVAT, foam cell, and plaque) were
analyzed by the one-way ANOVA (p < 0.050) and post hoc
Duncan tests after the preparation of aortic tissues from
the Wistar rats using a frozen section technique and coun-
ted for each of 10 fields under 400 magnification with
dotSlide OlyVia software (Olypmus America Inc., Center
Valley, PA, USA) (Figs. 1e3).Discussion
G. lucidum, a species of fungus, has been used in the
treatment of a wide range of diseases in Japan and China
for about 4000 years. G. lucidum is popular and has local
names such as Reishi in Japan and Ling Chu or Ling Zhi in
China and Korea. The traditional use of G. lucidum includesthe treatment of chronic diseases, such as hepatopathy,
chronic hepatitis, nephritis, hypertension, arthritis,
insomnia, bronchitis, asthma. G. lucidum has an antith-
rombolytic effect against atherosclerotic processes in
humans and is able to lower blood pressure and cholesterol
and blood glucose levels in animal models.12
Some bioactive substances have been identified and
isolated from G. lucidum, e.g., triterpenoids, poly-
saccharides, nucleosides, sterols, and alkaloids. These
substances are evidence of the functions and properties of
this fungus as an anti-inflammatory, antitumor, and anti-
oxidant agent.13 PsP from G. lucidum is mostly derived from
the (1/3)-b-D-glucans branch and acts through a type
three component (CR3 receptor), which is classed as a
(1/3)-b-D-glucans polysaccharide. b-D-Glucans is the major
component found in the G. lucidum mycelium.14
PsP has been shown to be beneficial in the treatment of
type 2 diabetes mellitus. One of its advantageous effects is
its ability to resolve the hypoglycemia and dyslipidemia
that cause high levels of cholesterol in type 2 diabetes
mellitus. A significant decrease in plasma glucose, phos-
phoenolpyruvate carboxykinase expression, and the body
weight of rats have been reported.15 PsP has also been
reported15 to have scavenger activity against free radicals,
although it is 100 times less potent than ascorbic acid
(vitamin C).
This study has shown a definite effect of the adminis-
tration of G. lucidum PsP on the reduction of histopatho-
logical images in rats in various treatment groups. Blood
glucose was measured twice in rats fed a hypercholesterol
Figure 1 Perivascular adipose tissue in different treatment groups of rats with type 2 diabetes mellitus. (A) Normal diet group;
(B) hypercholesterol diet group; (C) hypercholesterol diet group and PsP 50 mg/kg body weight; (D) hypercholesterol diet group and
PsP 150 mg/kg body weight; and (E) hypercholesterol diet group and PsP 300 mg/kg body weight.
Reduction of histopathological images 35diet and plasma insulin levels were determined. The dia-
betic rat models developed insulin resistance that signified
the existence of type 2 diabetes mellitus in rats receiving
the hypercholesterol diet.
The results of this study also support the use of G.
lucidum PsP as a suitable antioxidant agent in the treat-
ment of type 2 diabetes mellitus. A significant reduction in
H2O2, the lipid profile (total cholesterol and triglyceride),
insulin resistance and the amount of PVAT and plaques wasFigure 2 Foam cells in different treatment groups of rats wit
(A) Normal diet group; (B) hypercholesterol diet group; (C) hype
hypercholesterol diet group and PsP 150 mg/kg body weight; and (Eseen. However, the average number of foam cells after the
administration of various doses of PsP was insignificant
(one-way ANOVA, p < 0.050). This may occur as a result of
unknown technical failures in injecting STZ to induce type 2
diabetes mellitus or an incorrect method of administering
PsP to the rats. The optimum dose to give the highest
decrease in the histopathological images was 300 mg/kg
body weight, which was the highest dose of PsP in this
study.h type 2 diabetes mellitus (red arrows indicate foam cells).
rcholesterol diet group and psP 50 mg/kg body weight; (D)
) hypercholesterol diet group and PsP 300 mg/kg body weight.
Figure 3 Plaque in different treatment groups of rats with type 2 diabetes mellitus. (A) Normal diet group; (B) hypercholesterol
diet group; (C) hypercholesterol diet group and psP 50 mg/kg body weight; (D) hypercholesterol diet group and PsP 150 mg/kg body
weight; and (E) hypercholesterol diet group and PsP 300 mg/kg body weight.
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sumption through a hypercholesterol diet increases the
amount of free radicals inside the human body. PUFAs are
susceptible to various oxidative processes involving H2O2,
a substance generated by mitochondrial electron transfer.
The process of damage to PUFAs, lipid peroxidation, oc-
curs as a result of high levels of PUFA that undergo
hydrogen abstraction or the addition of oxygen radicals.
Transition metals, such as iron and copper, have been
proven to have pro-oxidant effects in their correlation
with H2O2 free radical activity. The continuous process of
lipid peroxidation finally ends with damage to structural
membranes, the inactivation of enzymes, and the pro-
duction of secondary products considered to be toxic to
cellular functions.16
The increase in fat deposition inside the body will induce
obesity after a certain period of time. Under normal con-
ditions, adiponectin has a role in preventing vascular al-
terations that progress to damage of the vessel walls. There
will be a negative correlation between adiponectin and
adiposity under conditions of high fat deposition. The
decreased level of adiponectin disrupts normal lipid and
glucose metabolism and finally causes insulin resistance
and hyperglycemia.17 Hyperglycemia affects the normal
endothelial function that stimulates the decrease in NO
production, the activation of NF-kB, and the increase in
pro-inflammatory and pro-thrombotic mediators. The cre-
ation and increase in the levels of ROS (H2O2) is induced by
the activation of NF-kB and is the source of endothelial
damage.18
Dysfunction of endothelial tissues as a result of the in-
crease in ROS (H2O2) is seen as increasing amounts of PVAT,
foam cells, and plaque deposits. The decrease in the his-
topathological results in this study is evidence of the ac-
tivity of G. lucidum PsP in prohibiting atherosclerotic
processes that end in vascular injury. Histhopatological
results, such as PVAT, foam cells, and plaque deposits,
which appear from injuries in vessel walls, are generated by
the increase in oxidative stress, the most important in type
2 diabetes mellitus being oxLDL. Hyperglycemia and dysli-
pidemia stimulate ROS such as H2O2 to progressively in-
crease and enable the production of oxLDL. oxLDL willadhere to the vessel walls and be seen as vessel wall
destruction on histopathological images. An antioxidant
substance is required to inhibit the free radicals that
damage blood vessels and G. lucidum PsP is promising in
this regard.
G. lucidum PsP also has an important role in restraining
cellular ischemia and necrosis from chronic inflammation
in atherosclerosis processes. PsP is able to reduce or
minimize the formation of foam cells that is evidence of
the decrease in vascular damage.19 The mechanism of PsP
in binding free radicals is expected to trigger the decrease
seen in the histopathological images after the formation of
foam cells.20 The decrease seen in the histopathological
images in this study strengthens the claim that PsP is
effective in preventing vascular damage in type 2 diabetes
mellitus. These results also support the view that PsP has
potent antioxidant powers as a scavenger against free
radicals. Future research on G. lucidum PsP should
consider its potency against other forms of vascular dam-
age. The beneficial effects of PsP administration need to
be confirmed to assess the possibility of including this
substance in the therapeutic management of type 2 dia-
betes mellitus.Conclusion
G. lucidum PsP can reduce endothelial dysfunction by
decreasing the histopathological images of aortic tissues of
Wistar rats with type 2 diabetes mellitus. G. lucidum PsP
prevents endothelial damage through its activity as an
antioxidant that inhibits oxidative stress, especially from
H2O2. The most effective dose of PsP to give the lowest
histopathological images in this study was 300 mg/kg body
weight. Future research on G. lucidum PsP is required to
further explore the advantages of PsP in the treatment of
type 2 diabetes mellitus.Conflicts of interest
The authors declare there are no conflicts of interests.
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